The Food and Drug Administration (FDA) on Thursday approved Aimovig, a new drug that would stop severe migraine headaches before they start.

By the numbers: The monthly self-injection treatment will cost $575 per month or $6,900 annually. Per the American Migraine Foundation, the neurological disease is the third most prevalent illness in the world, and over 36 million Americans suffer from migraines — more than those who have diabetes and asthma combined.